Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan

Clinical Rheumatology

Volumn 34, Issue 5, 2015, Pages 949-956

  Katada, Hirotaka ^a   Yukawa, Naoichiro ^a   Urushihara, Hisashi ^a   Tanaka, Shiro ^a   Mimori, Tsuneyo ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Anti rheumatic drugs; Claims database; Drug utilization study; Prescription patterns; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTHRITIS, RHEUMATOID; CLINICAL PRACTICE; DRUG COMBINATION; FACTUAL DATABASE; FEMALE; HUMAN; JAPAN; MALE; MIDDLE AGED;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS';

EID: 84891751276     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2482-1     Document Type: Article

References (43)

1. Smyth CJ (1968) Optimum therapeutic program in seropositive nodular rheumatoid arthritis. Med Clin North Am 52(3):687–698
2. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T (1989) Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16(5):585–591
3. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van’t Hof MA, van Rijswijk MH et al (1992) Biannual radiographic assessments of hands and feet in a three-year prospective follow up of patients with early rheumatoid arthritis. Arthritis Rheum 35(1):26–34
4. Fex E, Jonsson K, Johnson U, Eberhardt K (1996) Development of radiographic damage during the first 5–6 yr of rheumatoid arthritis: a prospective follow-up study of a Swedish cohort. Br J Rheumatol 35(11):1106–1115
5. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43(7):906–914
6. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56(5):1424–1432
7. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975
8. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204573
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639
10. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21(5):179–185
11. Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D et al (1993) Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 20(4):639–644
12. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39(2):272–276
13. Imokawa S, Colby TV, Leslie KO, Helmers RA (2000) Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 15(2):373–381
14. Pfizer Inc. Package insert for methotrexate (in Japanese). http://www.info.pmda.go.jp/downfiles/ph/PDF/671450_3999016M1021_2_10.pdf. Accessed 8 May 2013
15. Japan College of Rheumatology. Guidelines for adalimumab (in Japanese). 2008. https://www.ryumachi-jp.com/info/guideline_ADA.pdf. Accessed 8 May 2013
16. Japan College of Rheumatology. Guidelines for abatacept (in Japanese). 2010. https://www.ryumachi-jp.com/info/guideline_ABT_100930.pdf. Accessed 8 May 2013
17. Japan College of Rheumatology. Guidelines for tocilizumab (in Japanese). 2012. https://www.ryumachi-jp.com/info/guideline_TCZ.pdf. Accessed 8 May 2013
18. Japan Rheumatism Foundation. Guidelines for the management of rheumatoid arthritis (in Japanese). Ochi T, Yamamoto K, Ryu J, editors. 2013.
19. Kita F, Shibata Y, Yorifuji T, Nakahata T, Kawakami J, Kawakami K (2010) Prescription trends for treatment of paediatric gastroenteritis at a Japanese hospital between 1997 and 2007. J Clin Pharm Ther 35(1):87–92
20. Urushihara H, Doi Y, Arai M, Matsunaga T, Fujii Y, Iino N et al (2011) Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS One 6(12):e28483
21. Nakajima A, Inoue E, Shidara K, Hoshi D, Sato E, Seto Y et al (2011) Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006. Mod Rheumatol 21(6):594–597
22. Yamanaka H, Seto Y, Tanaka E, Furuya T, Nakajima A, Ikari K et al (2013) Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol 23(1):1–7
23. Yamanaka H, Tohma S (2006) Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 16(2):75–76
24. Yasui T, Nishino J, Kadono Y, Matsui T, Nakamura K, Tanaka S (2010) Impact of biologics on the prevalence of orthopedic surgery in the National Database of Rheumatic Diseases in Japan. Mod Rheumatol 20(3):233–237
25. Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R et al (2012) Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 71(11):1820–1826
26. Hashimoto S, Urushihara H, Hinotsu S, Kosugi S, Kawakami K (2012) Effect of HMG-CoA reductase inhibitors on blood pressure in hypertensive patients treated with blood pressure-lowering agents: retrospective study using an anti-hypertensive drug database. Eur Rev Med Pharmacol Sci 16(2):235–241
27. Statistics Bureau, Director-General for Policy Planning (Statistical Standards) and Statistical Research and Training Institute. DIVISION 87-DRUGS AND RELATED COMMODITIES (in Japanease). http://www.stat.go.jp/index/seido/syouhin/pdf/2cc8–87.pdf. Accessed 16 Dec 2013.
28. Schneeweiss S (2010) A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 19(8):858–868
29. Landau S, Everitt BS. A Handbook of Statistical Analyses using SPSS. Chapman & Hall/CRC Press LLC. In press. 2004:339p.
30. Tarone RE, Ware J (1977) On distribution free tests for equality of survival distributions. Biometrika 64:156–160
31. Mitsubishi Tanabe Pharmaceutical Company. Package insert for remicade (in Japanese). http://www.info.pmda.go.jp/downfiles/ph/PDF/400315_2399402F1026_1_26.pdf. Accessed 8 May 2013
32. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J et al (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63(7):797–803
33. Morrison E, Capell HA (2006) Corticosteroids in the management of early and established rheumatoid disease. Rheumatology 45:1058–1061
34. Iikuni N, Inoue E, Tanaka E, Hara M, Tomatsu T, Kamatani N et al (2008) Low disease activity state with corticosteroid may not represent ‘true’ low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47(4):519–521
35. Tanaka E, Mannalithara A, Inoue E, Iikuni N, Taniguchi A, Monohara S et al (2012) Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity. Rheumatol Int 32:749–757
36. Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C et al (2007) Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol 17(2):98–105
37. de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K (2010) Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital. Scand J Rheumatol 39(1):19–25
38. Yazici Y, Shi N, John A (2008) Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 66(2):77–85
39. Takeda Pharmaceutical Company. Package insert for enbrel (in Japanese). http://www.takedamed.com/content/medicine/pdf/126–130107.pdf. Accessed 8 May 2013
40. Chugai Pharmaceutical Company. Package insert for actemra (in Japanese). http://www.info.pmda.go.jp/go/interview/1/450045_6399421A1020_1_011_1F. Accessed 8 May 2013
41. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H et al (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67(2):189–194
42. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J et al (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36(5):898–906
43. Portal Site of Official Statistics of Japan, developed by Statistics Bureau, Ministry of Internal Affairs and Communications with the collaboration of Ministries and Agencies. http://www.e-stat.go.jp/SG1/estat/GL02020101.do?method=csvDownload&fileId=000006090759&releaseCount=1. Accessed 8 May 2013